Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study
Recruitment status was: Not yet recruiting
Recent data show that Rosiglitazone treatment can reduce proteinuria in diabetic patients. However, currently there are no trials that examine the effects of Rosiglitazone on kidney disease progression, that is, doubling of serum creatinine or time to onset of end-stage renal disease, in patients with diabetic nephropathy.
We decided to study retrospectively the possible association between rosiglitazone use and clinical course of diabetic nephropathy, including rate of deterioration of renal function, appearance and progression of microalbuminuria/proteinuria, survival and acceptance to renal replacement therapy.
Drug: Rosiglitasone (retrospective observation)
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
Time Perspective: Retrospective
|Official Title:||Retrospective Study Evaluating the Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study|
|Study Start Date:||August 2007|
|Estimated Study Completion Date:||December 2007|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00497666
|Clalit Health Cervices, Central District|
|Zerifin,, Israel, 70300|
|Principal Investigator:||Leonid S Feldman||Nephrology Division, Assaf Harofeh Medical Center, Zerifin,|
|Principal Investigator:||Leonid S Feldman||Assaf-Harofeh Medical Center|